Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X about a recent paper by Laure-Anne Teuwen et al. published on JNCI:
“This has always been our bottom line.”
Title: Success in oncology phase 3 trials: a small P value or patient value
Authors: Laure-Anne Teuwen, Gregory R Pond, Bishal Gyawali
Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, shared Bishal Gyawali’s post:
” ‘A surrogate endpoint is something a patient didn’t know was important until a doctor said it was’ – Adam Cifu”
More posts featuring Bishal Gyawali and Mark Lewis.